Inventiva S.A. ADR (IVA): Price and Financial Metrics

Inventiva S.A. ADR (IVA): $4.49

0.04 (+0.90%)

POWR Rating

Component Grades













IVA Stock Summary

  • Of note is the ratio of INVENTIVA SA's sales and general administrative expense to its total operating expenses; merely 6.69% of US stocks have a lower such ratio.
  • With a price/sales ratio of 19.24, INVENTIVA SA has a higher such ratio than 94.07% of stocks in our set.
  • In terms of volatility of its share price, IVA is more volatile than 89.49% of stocks we're observing.
  • Stocks that are quantitatively similar to IVA, based on their financial statements, market capitalization, and price volatility, are ARAV, FSR, GOVX, IMMP, and OPT.
  • IVA's SEC filings can be seen here. And to visit INVENTIVA SA's official web site, go to

IVA Stock Price Chart Interactive Chart >

Price chart for IVA

IVA Price/Volume Stats

Current price $4.49 52-week high $14.33
Prev. close $4.45 52-week low $3.49
Day low $4.35 Volume 362
Day high $4.49 Avg. volume 25,455
50-day MA $4.75 Dividend yield N/A
200-day MA $7.22 Market Cap 183.52M

Inventiva S.A. ADR (IVA) Company Bio

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

IVA Latest News Stream

Event/Time News Detail
Loading, please wait...

IVA Latest Social Stream

Loading social stream, please wait...

View Full IVA Social Stream

Latest IVA News From Around the Web

Below are the latest news stories about INVENTIVA SA that investors may wish to consider to help them evaluate IVA as an investment opportunity.

Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

New patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage This patent strengthens and expands the intellectual property protection of lanifibranor in the United States particularly for use for patients with cirrhotic NASH Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Compa

Yahoo | November 28, 2022

Inventiva announces a new Director of the Board of Directors

Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announces that, effective on November 9th, 2022, Inventiva’s board of directors coopted Dr. Lucy Lu as the Director of its Board of Directors in lieu of S

Yahoo | November 21, 2022

Inventiva reports 2022 Third Quarter Financial Information¹

Cash position2 at €72.6m as of September 30, 2022, not including the $12.6 million upfront payment received from Sino Biopharm on November 4, 2022Revenues of €0.1m for the first nine months of 2022 Daix (France), Long Island City (New York, United States), November 10, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepat

Yahoo | November 10, 2022

Inventiva Down After Development of Cedirogant Paused

Shares of Inventiva (NASDAQ: IVA) were down in pre-market trading as the clinical-stage biopharmaceutical company announced that AbbVie (ABBV) announced on Friday that it was stopping the development of cedirogant (ABBV- 157), a drug jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases. Frédéric Cren, Chairman, CEO, and Co-Founder of Inventiva commented, "Although we are disappointed to see the end of cedirogant’s clinical program following the analysis of a nonclinical toxicology study, we wish to thank our partner AbbVie for 10 years of collaboration.

Shrilekha Pethe on TipRanks | October 31, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back and get ready for another week of trading as we break down the biggest pre-market stock movers for Monday morning!

William White on InvestorPlace | October 31, 2022

Read More 'IVA' Stories Here

IVA Price Returns

1-mo 4.50%
3-mo 11.97%
6-mo -49.27%
1-year -67.11%
3-year N/A
5-year N/A
YTD -67.13%
2021 -5.79%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7934 seconds.